Agilent Technologies, Inc. · NYSE:A
Agilent Technologies — Q2 2018 Earnings Presentation
10 slides from Agilent Technologies's earnings presentation, May 2018
Slide 1: Agilent Technologies Q2'18 Results Presentation
Agilent Technologies Q2’18 Results Presentation
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements (including, without limitation, information and future guidance on the company’s goals, priorities, revenues, operating profit and operating margin, expected cash flow, growth opportunities, customer service and innovation plans, new
Slide 3: Agilent Results Q2'18
Agilent Results Q2'18 Scale and leading technology across Analytical Laboratories and Clinical & Dx markets Q2'18 Financial Metrics Q2’18 Headlines • Revenues: $1.21B, +4.3% y/y core(1)(2),+9.4% • Growth: Core growth finished at the mid-point of reported (+0.2% M&A, +4.9% FX). guidance led by strong
Slide 4: Life Sciences & Applied Markets Group (LSAG)
Life Sciences & Applied Markets Group (LSAG) Instrumentation and Informatics • Core revenue growth buoyed by Chemical & Energy for Analytical Laboratories offset weakness in Food and China. From a product perspective, LC/MS, Cell Analysis and ICP/MS led gains. • Operating Margin for the quarter was
Slide 5: Agilent Cross Lab Group (ACG)
Agilent Cross Lab Group (ACG) • Continued strong revenue performance led by Analytical Laboratory Consumables and Services Pharma, and Academia & Government. Gains were balanced across consumables and services. China delivered double-digit growth and all other major geographies grew mid to high-sing
Slide 6: Diagnostics and Genomics Group (DGG)
Diagnostics and Genomics Group (DGG) Pathology, Genomics, and Nucleic Acid Manufacturing • Revenue as expected led by strength in Reagents and Genomics. • Operating Margin for the quarter was 20.2%(1)(2), down 400 bps versus extraordinary Q2 last year (recognition of NASD supply agreement settlement
Slide 7: Growth in a $52B Market – Q2'18 Results by End Market
Growth in a $52B Market – Q2'18 Results by End Market Gains highlighted by solid Pharma and Chemical & Energy Analytical Laboratory End Markets Agilent Revenue by End Market (1) ▪ Q2'18 revenues: +5% y/y on core(2) basis ▪ Pharma & Biotech: Up 8% led by strength in mass spec, consumables and service
Slide 8: Profitable Growth Plan
Agilent Profitable Growth Plan Recent Actions ▪ Delivering on “Agile Agilent” Initiatives • Multi-year program to increase efficiency and customer focus. Operating Margin, adjusted for FX hedging losses, continued to expand in Q2. ▪ Portfolio Investments and “Go-to-Market” Capability • Plans announc
Slide 9: Strategy to Win
Agilent Strategy to Win Creating shareholder value ▪ Above Market Growth • Innovative, highly differentiated new products and solutions • Win enterprise lab-wide services & consumables - CrossLab • Accelerate bio-pharma penetration • Drive adoption of clinical genomics applications ▪ Aggressively ex
Slide 10: Q3'18 and FY18 Guidance and Forward-looking Considerations
Q3’18 and FY18 Guidance and Forward-looking Considerations Based on April 30, 2018 Exchange Rates FY18 Guidance • Revenue: $4.85B - $4.87B: growth at mid-point 5.5% core(4), 8.7% growth on unadjusted basis(1) (+0.2% M&A, +3.0% FX) • Operating Margin: 22.2% at mid-point or 22.4%(3) when adjusted for